🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Non-Hodgkin Lymphoma, B-cell

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site📍 Pittsburgh John Lister · Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE) NCT06534463n/a1 site📍 Shanghai Ruijin Hospital · Tests: All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the re… CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites📍 Chicago📍 Evanston📍 Providence AvenCell Therapeutics, Inc. · Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) NCT07059650Phase 1, Phase 213 sites📍 Beijing📍 Changsha📍 Chengdu Dizal Pharmaceuticals · Tests: DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites📍 Duarte📍 St Louis📍 Buffalo LTZ Therapeutics, Inc. · Tests: LTZ-301, LTZ-301, LTZ-301 A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites📍 Houston📍 Houston Baylor College of Medicine · Tests: C7R.CD30.CAR-EBVST cells Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma NCT07763210Phase 21 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease NCT05907759Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Daratumumab SC Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775NA7 sites📍 Berlin📍 Cologne📍 Erlangen Miltenyi Biomedicine GmbH · Tests: MB-CART19.1, MB-CART20.1, MB-CART2019.1 Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line NCT04670029Phase 35 sites📍 Besançon📍 Le Mans📍 Nancy Weprom · Tests: Adapted physical activity Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT03936153Phase 223 sites📍 Beijing📍 Beijing📍 Beijing Xynomic Pharmaceuticals, Inc. · Tests: abexinostat SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 Blinatumomab Consolidation in Real World NCT07117136n/a5 sites📍 Jacksonville📍 Chicago📍 Chicago Medical College of Wisconsin Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression NCT06005870Phase 21 site📍 Wuhan Huazhong University of Science and Technology · Tests: Zanubrutinib plus RCHOP Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma NCT06588205n/a20 sites📍 Alessandria📍 Ancona📍 Bari Fondazione Italiana Linfomi - ETS Prospective ctDNA Testing in Large B-Cell Lymphoma NCT07878351n/a2 sites📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Standard-of-care first-line immunochemotherapy containing an anti-CD20 monoclonal antibody and an anthracycline, such a… CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site📍 Prague Institute of Hematology and Blood Transfusion, Czech Republ… · Tests: Autologous CAR19 T lymphocytes R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden NCT05040555NA1 site📍 Changchun oubai, MD/PhD · Tests: R-CDOP Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma NCT04792502Phase 23 sites📍 New Haven📍 New Brunswick📍 Providence Brown University · Tests: Mosunetuzumab, Lenalidomide Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma NCT07439653Phase 1, Phase 29 sites📍 Fullerton📍 Los Alamitos📍 Santa Monica TORL Biotherapeutics, LLC · Tests: TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06015880Phase 18 sites📍 Duarte📍 Sacramento📍 Tampa National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients NCT05876923NA2 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Cardiopulmonary Exercise Testing, Dual X-ray Absorptiometry, Electronic Health Record Review, E… Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing NCT06550427n/a1 site📍 Taipei National Taiwan University Hospital · Tests: ctDNA analyzed by phased variant Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy NCT05757219Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy Wisconsin Ginseng for Decreasing Cancer Related Fatigue NCT06395441Phase 315 sites📍 Albert Lea📍 Bemidji📍 Brainerd Mayo Clinic · Tests: American Ginseng, Placebo Administration, Questionnaire Administration Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma NCT04840602Phase 2146 sites📍 Tucson📍 Tucson📍 Irvine National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy